|
内容記述 |
Uterine serous carcinoma (USC) is a rare aggressive type 2 endometrial carcinoma with high recurrence rate and dismal prognosis. Patients with USC often have peritoneal metastasis even from early stage. Trastuzumab, the anti-HER2 antibody, is clinically used to treat HER2 positive USC combining with conventional chemotherapy, however the acquired resistance to trastuzumab has been a challenge to overcome. Targeted alpha therapy (TAT) is useful not only to control local tumor but also metastasis. Astatine 211 (At-211) is one of the α- emitters that expected its clinical use because of the appropriate half-life and producible with cyclotron. We have demonstrated experimental TAT using [At-211]trastuzumab to preclinical mouse model with peritoneal metastasis of HER2 positive USC, which shown acquired trastuzumab treatment, to investigate the therapeutic efficacy and toxicity. We will discuss the potential of TAT as a novel therapeutic option for trastuzumab resistant peritoneal metastasis of HER2 positive USC. |
